Clinical efficacy of recombinant human brain natriuretic peptide on patients with acute myocardial infarction complicated with heart failure

Objective To explore the clinical efficacy of recombinant human brain natriuretic peptide (rhBNP) on treatment of acute myocardial infarction complicated with heart failure (AMI-HF). Methods A total of 92 in-hospital patients with AMI-HF were enrolled in the First Hospital of Shanxi Medical University. They were randomly divided into the observational group (n=44) and the control group(n=48). Patients in the control group were given routine treatment, while patients in observational group received routine treatment combired with rhBNP. The changes of urine volume, heart rate, creatinine clearance rate (cCr), N-terminal pro-brain natriuretic peptide (NT-proBNP), soluble ST2 (sST2), left ventricular ejection fraction (LVEF), left ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV) and main adverse cardiac events (MACE-) were recorded before and after usage of rhBNP. Results After treatment, heart rate, urine volume, cCr, NT-proBNP and sST2 levels of the two groups were all improved, but the improvement of observational group was more obvious than control group (P 0.05). Conclusion For AMI-HF patients, rhBNP can effectively improve cardiac function and reduce the incidence of MACE. Key words: Acute myocardial infarction; Heart failure; Recombinant human brain natriuretic peptide; Ventricular remodeling; incidence of MACE